Skip to main content
Erschienen in: Health Services and Outcomes Research Methodology 4/2020

12.09.2020

Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies

verfasst von: Heng Li, Wei-Chen Chen, Nelson Lu, Chenguang Wang, Ram Tiwari, Yunling Xu, Lilly Q. Yue

Erschienen in: Health Services and Outcomes Research Methodology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

In medical product development, there has been a growing interest in utilizing real-world data which have become abundant owing to advances in biomedical science, information technology and engineering. High-quality real-world data may be utilized to generate real-world evidence for regulatory or healthcare decision-making. We discuss propensity score-based approaches for leveraging patients from a real-world data source to construct a control group for a non-randomized comparative study or to augment a single-arm or randomized prospective investigational clinical study. The proposed propensity score-based approaches leverage real-world patients that are similar to those prospectively enrolled into the investigational clinical study in terms of baseline characteristics. Either frequentist or Bayesian inference can then be applied for outcome data analysis, with the option of down-weighting information from the real-world data source. Examples based on pre-market regulatory review experience are provided to illustrate the implementation of the proposed approaches.
Literatur
Zurück zum Zitat Chen, M.-H., Ibrahim, J.G.: Power prior distribution for regression models. Stat. Sci. 15(1), 46–60 (2000)CrossRef Chen, M.-H., Ibrahim, J.G.: Power prior distribution for regression models. Stat. Sci. 15(1), 46–60 (2000)CrossRef
Zurück zum Zitat Imbens, G.W., Rubin, D.B.: Causal Inference for Statistics, Social, and Biomedical Sciences. Cambridge University Press, New York (2015)CrossRef Imbens, G.W., Rubin, D.B.: Causal Inference for Statistics, Social, and Biomedical Sciences. Cambridge University Press, New York (2015)CrossRef
Zurück zum Zitat Inman, H.F., Bradley Jr., E.L.: The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities. Commun. Stat. Theory Methods 18(10), 3851–3874 (1989)CrossRef Inman, H.F., Bradley Jr., E.L.: The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities. Commun. Stat. Theory Methods 18(10), 3851–3874 (1989)CrossRef
Zurück zum Zitat Langenskold, S., Rubin, D.B.: Outcome-free design of observational studies: peer influence on smoking. Les Annales d’Economie et de Statistique 91(92), 107–125 (2008)CrossRef Langenskold, S., Rubin, D.B.: Outcome-free design of observational studies: peer influence on smoking. Les Annales d’Economie et de Statistique 91(92), 107–125 (2008)CrossRef
Zurück zum Zitat Li, H., Mukhi, V., Lu, N., Xu, Y., Yue, L.Q.: A note on good practice of objective propensity score design for premarket nonrandomized medical device studies with an example. Stat. Biopharm. Res. 8(3), 282–286 (2016)CrossRef Li, H., Mukhi, V., Lu, N., Xu, Y., Yue, L.Q.: A note on good practice of objective propensity score design for premarket nonrandomized medical device studies with an example. Stat. Biopharm. Res. 8(3), 282–286 (2016)CrossRef
Zurück zum Zitat Lu, N., Xu, Y., Yue, L.Q.: Good statistical practice in utilizing real world data in a comparative study for premarket evaluation of medical devices. J. Biopharm. Stat. 29(4), 580–591 (2019)CrossRef Lu, N., Xu, Y., Yue, L.Q.: Good statistical practice in utilizing real world data in a comparative study for premarket evaluation of medical devices. J. Biopharm. Stat. 29(4), 580–591 (2019)CrossRef
Zurück zum Zitat Lu, N., Xu, Y., Yue, L.Q.: Some considerations on design and analysis plan on a nonrandomized comparative study utilizing propensity score methodology for medical device premarket evaluation. Stat. Biopharm. Res. 12(2), 155–163 (2020)CrossRef Lu, N., Xu, Y., Yue, L.Q.: Some considerations on design and analysis plan on a nonrandomized comparative study utilizing propensity score methodology for medical device premarket evaluation. Stat. Biopharm. Res. 12(2), 155–163 (2020)CrossRef
Zurück zum Zitat Rosenbaum, P.R., Rubin, D.B.: The central role of the propensity score in observational studies for causal effects. Biometrika 70(1), 41–55 (1983)CrossRef Rosenbaum, P.R., Rubin, D.B.: The central role of the propensity score in observational studies for causal effects. Biometrika 70(1), 41–55 (1983)CrossRef
Zurück zum Zitat Rosenbaum, P.R., Rubin, D.B.: Reducing bias in observational studies using subclassification on the propensity score. JASA 79, 516–524 (1984)CrossRef Rosenbaum, P.R., Rubin, D.B.: Reducing bias in observational studies using subclassification on the propensity score. JASA 79, 516–524 (1984)CrossRef
Zurück zum Zitat Rubin, D.B.: Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv. Outcomes Res. Method. 2, 169–188 (2001)CrossRef Rubin, D.B.: Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv. Outcomes Res. Method. 2, 169–188 (2001)CrossRef
Zurück zum Zitat Rubin, D.B.: For objective causal inference, design trumps analysis. Ann. Appl. Stat. 2(3), 808–840 (2008)CrossRef Rubin, D.B.: For objective causal inference, design trumps analysis. Ann. Appl. Stat. 2(3), 808–840 (2008)CrossRef
Zurück zum Zitat Varin, C., Reid, N., Firth, D.: An overview of composite likelihood methods. Stat. Sin. 21, 5–42 (2011) Varin, C., Reid, N., Firth, D.: An overview of composite likelihood methods. Stat. Sin. 21, 5–42 (2011)
Zurück zum Zitat Wang, C., Li, H., Chen, W., Lu, N., Tiwari, R., Xu, Y., Yue, L.Q.: Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies. J. Biopharm. Stat. 29(5), 731–748 (2019)CrossRef Wang, C., Li, H., Chen, W., Lu, N., Tiwari, R., Xu, Y., Yue, L.Q.: Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies. J. Biopharm. Stat. 29(5), 731–748 (2019)CrossRef
Zurück zum Zitat Xu, Y., Lu, N., Yue, L.Q., Tiwari, R.: A study design for augmenting the control group in a randomized controlled trial: a quality process for interaction among stakeholders. Thera. Innov. Regul. Sci. 54(2), 269–274 (2020)CrossRef Xu, Y., Lu, N., Yue, L.Q., Tiwari, R.: A study design for augmenting the control group in a randomized controlled trial: a quality process for interaction among stakeholders. Thera. Innov. Regul. Sci. 54(2), 269–274 (2020)CrossRef
Zurück zum Zitat Yue, L.Q., Lu, N., Xu, Y.: Designing pre-market observational comparative studies using existing data as controls: challenges and opportunities. J. Biopharm. Stat. 24, 994–1010 (2014)CrossRef Yue, L.Q., Lu, N., Xu, Y.: Designing pre-market observational comparative studies using existing data as controls: challenges and opportunities. J. Biopharm. Stat. 24, 994–1010 (2014)CrossRef
Zurück zum Zitat Yue, L.Q., Campbell, G., Lu, N., Xu, Y., Zuckerman, B.: Utilizing national and international registries to enhance pre-market medical device regulatory evaluation. J. Biopharm. Stat. 26(6), 1136–1145 (2016)CrossRef Yue, L.Q., Campbell, G., Lu, N., Xu, Y., Zuckerman, B.: Utilizing national and international registries to enhance pre-market medical device regulatory evaluation. J. Biopharm. Stat. 26(6), 1136–1145 (2016)CrossRef
Metadaten
Titel
Novel statistical approaches and applications in leveraging real-world data in regulatory clinical studies
verfasst von
Heng Li
Wei-Chen Chen
Nelson Lu
Chenguang Wang
Ram Tiwari
Yunling Xu
Lilly Q. Yue
Publikationsdatum
12.09.2020
Verlag
Springer US
Erschienen in
Health Services and Outcomes Research Methodology / Ausgabe 4/2020
Print ISSN: 1387-3741
Elektronische ISSN: 1572-9400
DOI
https://doi.org/10.1007/s10742-020-00218-4

Weitere Artikel der Ausgabe 4/2020

Health Services and Outcomes Research Methodology 4/2020 Zur Ausgabe